A Novel Study of Protein Kinase C Beta Gene Polymorphism (rs3760106) and Protein Kinase C Activity Levels as a Predictor of Nephropathy Complications in Iraqi Diabetic Patients


  • Fadhil Jawad Al-Tu’ma Department of Chemistry and Biochemistry, College of Medicine, University of Kerbala, Kerbala, Iraq.
  • Zahraa Abdul Adheem Al-Maiyaly Department of Chemistry and Biochemistry, College of Medicine, University of Kerbala, Kerbala, Iraq.




Type 2 diabetic nephropathy, PRKCB gene polymorphism, pathogenesis, protein kinase C


Objective: This study aimed to investigate the relation between the risk of (PRKCB-1504 C/T) gene polymorphisms and diabetic nephropathy pathogenesis and its association with its levels and some other biomarkers in serum of Iraqi diabetic nephropathy patients.

Methods: A cross-sectional study was performed on 130 samples obtained from Al-Hussein Teaching Hospital / Kerbala – Iraq during Feb., 2020 to March. 2021. Seventy three patients of them with type 2 diabetes mellitus (T2D) and the remaining patients with type 2 diabetes mellitus with nephropathy complications (DN). Phenotypic analysis included determination of protein kinase C (PKC) activity levels, HbA1c%, serum insulin levels and renal function tests. Five ml of whole blood was obtained from each patients, 4.0 ml was centrifuged for serum separation used for biomarkers determinations and the remaining 1.0 ml was used for genomic DNA extraction for molecular analysis and polymorphism of PRKCB (rs3760106) by allele specific-amplification refractory mutational system-polymerase chain reaction (allele specific ARMS-PCR), followed by electrophoresis on 1% agarose gel. Various statistical analyses were applied to analyze the obtained data.

Results: The amplification of the PRKCB gene gives one genotypes as indicated by (200 bp) bands for those with homozygous wild type (CC), homozygous mutant (TT) genotypes and two genotypes bands (200 bp) for those with heterozygous (CT). Genotype frequencies of rs3760106 polymorphism were found to be consistent with Hardy–Weinberg equilibrium. Allele frequencies (23.3 %, 26.7 %, 50 %) of CC, CT, TT in cases of DN group. While the frequencies in the non-DN group were (30 %, 45%, 25%) and for healthy control group were (50%, 33.4%, 16.6%) for wild, heterozygous, and homozygous in an order. In healthy control group, the risk of diabetic nephropathy was significantly  higher among carriers of T allele under codominant TT (OR=6.42, 95%CI=(1.66-24.85), P=0.007), dominant CT+TT (OR=3.2, 95%CI = (1.08-9.95),P=0.03) and recessive model  (OR=5, 95%CI = (1.51-16.56), P=0.008) while in T2DM without nephropathy the risk of diabetic nephropathy was significantly higher among carrier of T allele under recessive model (0R=3, 95%CI = (1.09-28.25), P= 0.003). Serum level of PKC-B1 activity was significantly higher among DN group than T2DM and control groups (43.35 ± 18.69, 30.35 ± 11.96, 27.42 ± 10.31, P=0.001), also PKC-B1 activity in DN group was significantly correlated with fasting blood glucose, HOMA-IR and renal function tests such as GFR, urea and creatinine.

Conclusion: This study indicates that the PRKCB (C/T-1504) rs3760106 single nucleotide polymorphism was significantly associated with increased diabetic nephropathy susceptibility of Iraqi patients with T2DM and serum level of PKCB activity was associated with increase the risk of diabetic nephropathy complications.


Ahlqvist, E., Ahluwalia, T. S. and Groop, L. (2011). Genetics of type 2 diabetes. Clinical chemistry, 57 : 241-254.

Al - Tu'ma, A. F., Jeddoa, Z.M. and El–Yassin, H. D. (2019). Molecular Basis of Gene Encoding Human Leukocyte Antigens and its Association with Type 1 Diabetes Mellitus in Children of Kerbala Province. WJPMR, 5(1) : 218-225.

Al-Tu’ma, F.J. and Obed K. H. (2018). Association between Fat Mass and Obesity Associated (FTO) gene polymorphism (rs9939609) and lipid profile in type 2 diabetic obese Iraqi male. Iraq Med J, 2 (1) : 15–19.

Al-Tu’ma, F.J. ; Dheyauldeen, M.H. and Al-Saegh, R.M. (2017). Measurement of urinary kidney injury molecule-1 as a predictive biomarker of contrast-induced acute kidney injury. J Contemp Med Sci., 3(9) : 178–181

Al-Koofee, D. A., and Mobarak, S. M. (2018). PRIMER1: a network service for tetra-arms PCR primer design based on well-known dbSNP. Research Journal of Pharmacy and Technology, 11(8) : 3633-37.‏

Araki, S. I., Ng, D. P., Krolewski, B., Wyrwicz, L.,Rogus, J. J., Canani, L. and Krolewski, A. S. (2003). Identification of a common risk haplotype for diabetic nephropathy at the protein kinase C-β1 (PRKCB1) gene locus. Journal of the American Society of Nephrology, 14(8) :2015-2024.‏

Becker, K. P. and Hannun, Y. A. (2004). Isoenzyme-specific translocation of PKCbII and not PKCbI to a Juxtanuclear subset of recycling endosomes. Involvement of phospholipase D. Journal of Biological Chemistry, 279 : 28251 – 56.

Do Van, B.; Gouel, F.; Jonneaux, A.; Timmerman, K.; Gelé, P.; Pétrault, M.; Bastide, M.; Laloux, C.; Moreau, C.; Bordet, R. (2016). Ferroptosis, a newly characterized form of cell death in Parkinson’s disease that is regulated by PKC. Neurobiol. Dis., 94 : 169–178.

Gordon, R.; Singh, N.; Lawana, V.; Ghosh, A.; Harischandra, D.S.; Jin, H.; Hogan, C.; Sarkar, S.; Rokad, D.; Panicker, N. (2016). Protein kinase Cδ up-regulation in microglia drives neuro-inflammatory responses and dopaminergic neuro-degeneration in experimental models of Parkinson’s disease. Neurobiol. Dis. , 93 : 96–114.

Hashemi, M., Hoseini, H., Yaghmaei, P., (2011). Association of polymorphisms in glutamate-cysteine ligase catalytic subunit and microsomal triglyceride. DNA Cell Biol. 30 (8) : 569 – 75.

Heindel, J. J., Blumberg, B., Cave, M., Machtinger, R., Mantovani, A., Mendez, M. A. and Vandenberg, L. N. (2017). Metabolism disrupting chemicals and metabolic disorders. Reproductive toxicology, 68 : 3-33.

Jain, A. K. C., Apoorva, H. C., Kumar, H., Kumar, K., and Rajagopalan, S. (2018). Analyzing diabetic foot ulcer through Amit Jain’s classification: a descriptive study. Int J SurgSci, 2(4), 26-32.‏(1) : 569–575.

Kirouac, L.; Rajic, A.J.; Cribbs, D.H.; Padmanabhan, J. (2017). Activation of Ras-ERK signaling and GSK-3 by amyloid precursor protein and amyloid beta facilitates neurodegeneration in Alzheimer’s disease. Eneuro, 4 (2) : 0149

Kishimoto, A.; Takai, Y.; Mori, T.; Kikkawa, U.; Nishizuka, Y. (1980) Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. J. Biol. Chem., 255 : 2273–2276.

Kwak, S. H. and Park, K. S. (2015). Genetic Studies on Diabetic Microvascular Complications: Focusing on Genome-Wide Association Studies. Endocrinol Metab, 30 :147-158.

Langham, R. G., Kelly, D. J., Gow, R. M., Zhang, Y., Cox, A. J., Qi, W. and Gilbert, R. E. (2008). Increased renal gene transcription of protein kinase C-β in human diabetic nephropathy: relationship to long-term glycaemic control. Diabetologia, 51(4) : 668-674.

Ma, R. C., Tam, C. H., Wang, Y., Luk, A. O., Hu, C., Yang, X. and Tong, P. C. (2010). Genetic variants of the protein kinase C-β 1 gene and development of end-stage renal disease in patients with Type 2 diabetes. Jama, 304(8) : 881-889.‏

Mérida, I., Arranz-Nicolás, J., Rodríguez-Rodríguez, C., and Ávila-Flores, A. (2019). Diacylglycerol kinase control of protein kinase C. Biochemical Journal, 476(8) : 1205-1219.‏

Noh, H., and King, G. L. (2007). The role of protein kinase C activation in diabetic nephropathy. Kidney International, 72 : S49-S53.‏

Noor, T., Hanif, F., Kiran, Z., Rehman, R., Khan, M. T., Haque, Z., and Nankani, K. (June 2020). Relation of Copeptin with Diabetic and Renal Function Markers Among Patients with Diabetes Mellitus Progressing Towards Diabetic Nephropathy. Archives of Medical Research, 03 , 51(6) : 548-555

Patel, N. A., Yamamoto, M., Illingworth, P., Mancu, D., Mebert, K., Chappell, D. S. and Cooper, D. R. (2002). Phosphoinositide-3-kinase mediates protein kinase C βII mRNA destabilization in rat A10 smooth muscle cell cultures exposed to high glucose. Archives of biochemistry and biophysics, 403(1) : 111-120.‏

Schena, F. P. and Gesualdo, L. (2005). Pathogenetic mechanisms of diabetic nephropathy. Journal of the American Society of Nephrology, 16 (3 suppl 1) : S30-S33.‏

Stumvoll, M., Goldstein, B. J. and Van Haeften, T. W. (2005). Type 2 diabetes: principles of pathogenesis and therapy. The Lancet, 365 : 1333-1346.

Tan, . J. H., Hong, C. C., Shen, . L. and TAY, . E. Y., 2015. Costs of Patients Admitted for Diabetic Foot Problems. Ann Acad Med Singapore, 44(12) : 567-570.

Toyoda, M., Suzuki, D., Honma, M., Uehara, G., Sakai, T., Umezono, T. and Sakai, H. (2004). High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney international, 66(3) : 1107-1114.‏

Wang, Z. B., Zhang, S., Li, Y., Wang, R. M., Tong, L. C., Wang, Y. and Li, L. (2017). LY333531, a PKCβ inhibitor, attenuates glomerular endothelial cell apoptosis in the early stage of mouse diabetic nephropathy via down-regulating swiprosin-1. Acta Pharmacologica Sinica, 38(7) : 1009-1023.‏

Warren, A. M., Knudsen, S. T., and Cooper, M. E. (2019). Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies. Expert opinion on therapeutic targets, 23(7) : 579-591.‏

Wei, L., Xiao, Y., Li, L., Xiong, X., Han, Y., Zhu, X. and Sun, L. (2018). The Susceptibility Genes in Diabetic Nephropathy. Kidney Diseases, 4 :226-237.

Yang, J., and Zhang, J. (2015). Influence of protein kinase C (PKC) on the prognosis of diabetic nephropathy patients. International Journal of Clinical and Experimental Pathology, 8(11) : 14925.‏



How to Cite

Al-Tu’ma, F. J. ., & Al-Maiyaly, Z. A. A. . (2022). A Novel Study of Protein Kinase C Beta Gene Polymorphism (rs3760106) and Protein Kinase C Activity Levels as a Predictor of Nephropathy Complications in Iraqi Diabetic Patients. Journal of Contemporary Medical Sciences, 8(2). https://doi.org/10.22317/jcms.v8i2.1204